Biomarker Analysis Services for Kidney Fibrosis
Ace Therapeutics offers specialized biomarker analysis services dedicated to advancing drug discovery and preclinical development for Kidney Fibrosis research. Our comprehensive biomarker panel is designed to elucidate the complex pathophysiology of kidney fibrosis, supporting the identification and characterization of molecular targets relevant to disease progression and therapeutic intervention. Please note that our services are exclusively focused on research and drug discovery through preclinical stages and do not include clinical diagnostic services.
Effective therapeutic intervention in Kidney Fibrosis begins with robust biomarker discovery and identification. At Ace Therapeutics, our biomarker discovery services provide a foundation for drug development by enabling the identification of molecular indicators associated with disease onset, progression, and therapeutic response. Our approach integrates high-throughput screening and rigorous validation processes, including in silico analyses, in vitro assays, and preclinical in vivo models, to ensure the relevance and reliability of potential biomarkers for further development.
Multi Omics: Leveraging cutting-edge -omics technologies, Ace Therapeutics employs genomics, transcriptomics, proteomics, and metabolomics to comprehensively study biological systems implicated in kidney fibrosis. This multi-omics approach enables the identification of DNA, RNA, protein, and metabolite biomarkers, providing a holistic view of molecular alterations driving disease. Through integrative analysis, we interrogate key pathways such as TGF-β signaling, extracellular matrix remodeling, immune modulation, and fibrogenesis, all central to the pathogenesis of Kidney Fibrosis.
Candidate Validation: Our candidate validation strategies are designed to confirm the association of discovered biomarkers with Kidney Fibrosis pathophysiology. Preliminary screening involves quantitative and qualitative assessments in relevant preclinical models, supported by literature mining and pathway analysis. Promising candidates are prioritized based on specificity, sensitivity, biological relevance, and feasibility for assay development, ensuring alignment with drug discovery objectives.
Diverse Technological Platforms: Ace Therapeutics offers custom assay development tailored to the unique requirements of Kidney Fibrosis research. Our platforms are adaptable, supporting a range of analytical formats including immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and histopathology/imaging. This flexibility ensures precise quantification and characterization of diverse biomarker types across multiple sample matrices.
Immunoassays: We utilize ELISA, chemiluminescent, and multiplex immunoassays for sensitive and specific quantification of protein biomarkers such as cytokines and extracellular matrix proteins.
Mass Spectrometry: Our LC-MS/MS platforms enable targeted and untargeted proteomic and metabolomic profiling, facilitating the detection of low-abundance molecular species.
Flow Cytometry: Flow cytometry is employed for cellular phenotyping and quantification of cell surface or intracellular biomarkers in kidney tissue and blood-derived cells.
Molecular Diagnostics: We implement nucleic acid-based methods, including qPCR and digital PCR, for precise measurement of gene and microRNA expression relevant to fibrotic pathways.
Histopathology And Imaging: Advanced histopathology and imaging techniques, including immunohistochemistry and digital pathology, provide spatial and morphological context for biomarker localization in kidney tissue.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with established research guidelines. We assess key performance characteristics such as accuracy, precision, sensitivity, specificity, linearity, and reproducibility. Stringent quality control measures are implemented throughout, including the use of reference standards, controls, and inter-assay comparisons to ensure data integrity and reliability.
Our quantitative analysis capabilities enable precise measurement of biomarker levels across a range of concentrations. Standard curves, internal controls, and calibration procedures are integrated into each workflow to ensure robust quantitation, supporting downstream data interpretation and decision-making in preclinical research.
Sample Analysis: Ace Therapeutics handles a variety of sample types, including tissue, blood, plasma, serum, urine, and cell lysates, relevant to Kidney Fibrosis research. Standardized protocols are applied for sample preparation, storage, and analysis to minimize variability. Comprehensive quality assurance processes, including sample tracking and integrity checks, are maintained throughout the analytical pipeline.
High Throughput Capabilities: Our high-throughput analytical platforms, including multiplex immunoassays and automated sample processing systems, enable efficient analysis of large sample cohorts. This approach conserves valuable samples, reduces assay time, and increases data output, facilitating rapid screening and prioritization of biomarker candidates in preclinical studies.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| SMAD family member 3 (SMAD3) | SMAD family member 3 (SMAD3) is a transcription factor that plays a central role in the transforming growth factor-beta (TGF-β) signaling pathway. Upon activation of TGF-β receptors, SMAD3 is phosphorylated and forms a complex with SMAD4, which then translocates to the nucleus to regulate the expression of target genes. SMAD3 is involved in various cellular processes including cell proliferation, differentiation, apoptosis, and extracellular matrix production. It is particularly important in regulating immune responses, tissue fibrosis, and development. | SMAD3 expression and phosphorylation status have been studied as biomarkers in several disease contexts. Elevated or altered SMAD3 activity has been associated with fibrotic diseases such as liver, lung, and kidney fibrosis. In oncology, SMAD3 has been investigated in relation to tumor progression and metastasis, particularly in cancers where TGF-β signaling is dysregulated. Additionally, genetic variants in SMAD3 have been linked to susceptibility to conditions such as osteoarthritis and cardiovascular diseases. Measurement of SMAD3 levels or activity can provide information on disease state, progression, or response to therapy in these contexts. |
| SPARC related modular calcium binding 2 (SMOC2) | SPARC related modular calcium binding 2 (SMOC2) is a member of the SPARC (secreted protein acidic and rich in cysteine) family of matricellular proteins. SMOC2 is a secreted glycoprotein characterized by the presence of multiple calcium-binding domains, including two EF-hand motifs and a follistatin-like domain. It is involved in the regulation of extracellular matrix (ECM) organization and remodeling, and has been shown to modulate cell-matrix interactions, cell adhesion, migration, and angiogenesis. SMOC2 can interact with matrix components and growth factors, influencing signaling pathways such as BMP (bone morphogenetic protein) and TGF-β (transforming growth factor beta). Its expression is observed in various tissues, including the vasculature, kidney, and connective tissue, and it plays roles in tissue development, wound healing, and fibrosis. | SMOC2 has been investigated as a biomarker in several disease contexts. Elevated expression levels of SMOC2 have been reported in certain cancers, such as colorectal, gastric, and hepatocellular carcinoma, where its presence in tumor tissue or serum has been associated with tumor progression and prognosis. Additionally, altered SMOC2 expression has been observed in fibrotic diseases, including idiopathic pulmonary fibrosis and renal fibrosis, as well as in cardiovascular pathologies. Its detection in tissue or body fluids has been explored for potential use in disease diagnosis, prognosis, and monitoring, particularly in oncology and fibrotic disorders. |
| cadherin 11 (CDH11) | Cadherin 11 (CDH11) is a type II classical cadherin, which belongs to the cadherin superfamily of calcium-dependent cell-cell adhesion molecules. CDH11 is primarily expressed in mesenchymal tissues, including osteoblasts, fibroblasts, and synovial cells. It mediates homophilic cell adhesion and plays a critical role in tissue morphogenesis, maintenance of tissue architecture, and regulation of cell migration and signaling. CDH11 is involved in processes such as bone development, synovial joint formation, and the regulation of cellular differentiation within mesenchymal lineages. | CDH11 has been studied as a biomarker in several pathological conditions. In oncology, altered expression of CDH11 has been observed in various cancers, including breast, prostate, and colorectal cancers, where it may correlate with tumor progression, invasiveness, or metastatic potential, particularly to bone. In rheumatology, elevated CDH11 expression in synovial fibroblasts has been associated with rheumatoid arthritis, reflecting its involvement in synovial tissue remodeling and inflammation. These associations have led to the investigation of CDH11 as a potential diagnostic or prognostic biomarker in these contexts. |
| cellular communication network factor 2 (CCN2) | Cellular communication network factor 2 (CCN2), also known as connective tissue growth factor (CTGF), is a matricellular protein belonging to the CCN family. CCN2 is involved in diverse cellular processes, including cell adhesion, migration, proliferation, differentiation, and extracellular matrix (ECM) production. It plays a key role in tissue development, wound healing, and fibrosis by interacting with integrins, growth factors, and ECM components. CCN2 modulates signaling pathways such as TGF-β, Wnt, and VEGF, influencing angiogenesis, chondrogenesis, and fibrogenesis. Its expression is tightly regulated in normal physiology but is often upregulated in response to tissue injury and during fibrotic processes. | CCN2 has been studied as a biomarker in various pathological conditions, particularly those involving tissue fibrosis and remodeling. Elevated levels of CCN2 have been detected in fibrotic diseases such as systemic sclerosis, liver fibrosis, and kidney fibrosis, as well as in certain cancers. Measurement of CCN2 expression in tissues or body fluids (e.g., blood, urine) has been explored for its potential to indicate disease presence, severity, or progression, especially in fibrotic and oncological contexts. |
| fibroblast activation protein alpha (FAP) | Fibroblast activation protein alpha (FAP) is a type II transmembrane serine protease belonging to the dipeptidyl peptidase IV (DPPIV) family. FAP exhibits both dipeptidyl peptidase and endopeptidase enzymatic activities. It is minimally expressed in most adult tissues but is upregulated in activated fibroblasts, particularly in the context of tissue remodeling, wound healing, and fibrotic processes. FAP is prominently expressed in cancer-associated fibroblasts (CAFs) within the tumor stroma, where it can modulate the extracellular matrix by degrading components such as gelatin and type I collagen. Through these activities, FAP is implicated in tissue remodeling, cell migration, and potentially in the regulation of immune responses within the tumor microenvironment. | FAP has been studied as a biomarker for identifying activated fibroblasts in various pathological conditions, particularly in cancer and fibrotic diseases. Its elevated expression in the stroma of many epithelial cancers, such as colorectal, breast, and pancreatic carcinomas, has been utilized for tumor detection and imaging using FAP-targeted probes. Additionally, FAP expression has been investigated as an indicator of stromal activation in fibrotic diseases, including pulmonary and cardiac fibrosis. Its restricted expression in normal tissues and upregulation in pathological states make it a candidate for distinguishing diseased from non-diseased tissue in research and clinical settings. |
| microRNA 21 (MIR21) | microRNA 21 (MIR21) is a small, non-coding RNA molecule that functions primarily as a post-transcriptional regulator of gene expression. MIR21 binds to complementary sequences in the 3' untranslated regions (3' UTRs) of target messenger RNAs (mRNAs), leading to mRNA degradation or inhibition of translation. It is widely expressed in various tissues and has been shown to regulate cellular processes such as proliferation, apoptosis, and differentiation. MIR21 is known to target multiple genes involved in tumor suppression, cell cycle regulation, and apoptosis, including PTEN, PDCD4, and TPM1. Its dysregulation has been associated with altered cellular signaling pathways, particularly those involved in cancer and inflammatory responses. | MIR21 has been studied as a biomarker in several disease contexts, most notably in oncology. Elevated levels of MIR21 have been detected in tumor tissues and body fluids (such as blood, plasma, and serum) of patients with various cancers, including breast, lung, colorectal, and gastric cancers. Its expression has been investigated for potential utility in cancer diagnosis, prognosis, and monitoring of disease progression or response to therapy. In addition to oncology, MIR21 levels have been explored in relation to cardiovascular diseases and inflammatory conditions. Its stability in biofluids and relative abundance make it a candidate for non-invasive biomarker studies. |
| periostin (POSTN) | Periostin (POSTN) is a secreted extracellular matrix protein that plays a significant role in tissue development and remodeling. It is involved in cell adhesion, migration, and proliferation, particularly in connective tissues. POSTN interacts with integrins on cell surfaces, influencing signaling pathways that regulate cell survival and motility. It is highly expressed during embryonic development, wound healing, and in response to tissue injury. In adults, POSTN contributes to the maintenance of tissue integrity and has been implicated in processes such as fibrosis, inflammation, and angiogenesis. | Periostin has been studied as a biomarker in several clinical contexts due to its elevated expression in various pathological conditions. In asthma and other allergic diseases, increased periostin levels in serum and tissues have been associated with type 2 airway inflammation. It has also been investigated as a marker for tissue remodeling and fibrosis in conditions such as idiopathic pulmonary fibrosis and cardiac fibrosis. Additionally, periostin expression has been explored in oncology, where its presence in tumor tissues or bodily fluids may correlate with tumor progression, metastasis, or prognosis in certain cancers. |
| signal transducer and activator of transcription 3 (STAT3) | Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT protein family. It functions as a transcription factor that is activated in response to cytokines and growth factors, such as interleukin-6 (IL-6), epidermal growth factor (EGF), and others. Upon activation, STAT3 is phosphorylated, dimerizes, and translocates to the nucleus, where it binds to specific DNA response elements to regulate the expression of target genes. STAT3 is involved in various biological processes, including cell growth, differentiation, survival, immune response, and inflammation. It plays a key role in mediating signaling pathways that control cell proliferation and apoptosis, and is implicated in normal physiological processes as well as pathological conditions when dysregulated. | STAT3 has been utilized as a biomarker in a range of research and clinical contexts, particularly in oncology and inflammatory diseases. Its expression levels and activation status (e.g., phosphorylated STAT3) have been assessed in tumor tissues and blood samples to investigate associations with disease progression, prognosis, and therapeutic response. Elevated STAT3 activity has been observed in various cancers, including breast, lung, and colorectal cancers, and is often correlated with poor clinical outcomes. Additionally, STAT3 activation has been studied as an indicator of inflammation in autoimmune and infectious diseases. Its measurement is commonly performed using immunohistochemistry, Western blotting, or ELISA-based methods. |
| transforming growth factor beta 1 (TGFB1) | Transforming growth factor beta 1 (TGFB1) is a multifunctional cytokine that is part of the TGF-beta superfamily. It plays a critical role in regulating cell proliferation, differentiation, apoptosis, and extracellular matrix production. TGFB1 is involved in immune system modulation, wound healing, and the maintenance of tissue homeostasis. It exerts its effects by binding to TGF-beta receptors, which activate intracellular SMAD signaling pathways, leading to transcriptional regulation of target genes. TGFB1 is also implicated in the regulation of inflammation and fibrosis, influencing processes such as epithelial-to-mesenchymal transition and immune cell function. | TGFB1 has been studied as a biomarker in various pathological conditions, including fibrotic diseases, cancer, and autoimmune disorders. Elevated levels of TGFB1 in tissue or biological fluids have been associated with the presence and progression of fibrotic processes, such as those seen in liver fibrosis, pulmonary fibrosis, and renal fibrosis. In oncology, TGFB1 expression has been correlated with tumor progression, metastasis, and immune evasion. Measurement of TGFB1 levels may provide information on disease activity, prognosis, and response to therapy in specific clinical contexts. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine produced primarily by activated macrophages and other immune cells. It plays a central role in the regulation of immune responses, inflammation, and apoptosis. TNF exerts its effects by binding to specific cell surface receptors (TNFR1 and TNFR2), leading to the activation of signaling pathways such as NF-κB and MAPK. These pathways mediate processes including the induction of other cytokines, cell survival, proliferation, differentiation, and programmed cell death. TNF is involved in host defense against infections and tumor surveillance but is also implicated in the pathogenesis of various inflammatory and autoimmune diseases. | TNF levels in blood, tissues, or other biological fluids have been measured as an indicator of inflammatory activity in various clinical contexts. Elevated TNF concentrations have been observed in conditions such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. Quantification of TNF can aid in assessing disease activity, monitoring response to anti-TNF therapies, and providing prognostic information in inflammatory and infectious diseases. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services offer a robust platform for the exploration and characterization of molecular targets relevant to Kidney Fibrosis. With expertise in multi-omics, custom assay development, and advanced analytical methods, we support the discovery and validation of research biomarkers throughout preclinical drug development. Please note that all biomarkers discussed are research targets only; we do not claim any as validated or mandatory for any application. Our focus is strictly on preclinical research, and our approach maintains the highest standards of scientific objectivity.
We invite you to engage with Ace Therapeutics in collaborative discussions about biomarker research for Kidney Fibrosis. Our services are designed for exploratory research and scientific knowledge exchange. Connect with us to explore how our expertise can support your preclinical research objectives.
Make Order
Experimental Scheme
Implementation
Conclusion
